The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis

被引:25
|
作者
Kumar, Virender [1 ]
Dong, Yuxiang [1 ]
Kumar, Vinod [1 ]
Almawash, Saud [1 ]
Mahato, Ram I. [1 ]
机构
[1] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, 986025 Nebraska Med Ctr, Omaha, NE 68198 USA
来源
THERANOSTICS | 2019年 / 9卷 / 25期
关键词
Liver fibrosis; Hedgehog; MDB5; GDC-0449; HEPATIC STELLATE CELLS; POLYMERIC MICELLES; OSTEOPONTIN; BIODISTRIBUTION; ACTIVATION; EXPRESSION; MIRNA; YAP; PHARMACOKINETICS; MATRIX;
D O I
10.7150/thno.38913
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rationale: Hedgehog (Hh) pathway plays an essential role in liver fibrosis by promoting the proliferation of hepatic stellate cells (HSCs) by enhancing their metabolism via yes-associated protein 1 (YAP1). Despite the presence of several inhibitors, Hh signaling cannot be controlled exclusively due to their poor efficacy and the lack of a suitable delivery system to the injury site. Therefore, it is rationale to develop new potent Hh inhibitors and suitable delivery carriers. Methods: Based on the structure and activity of Hh inhibitor GDC-0449, we replaced its sulfonamide group with two methylpyridine-2yl at amide nitrogen to synthesize MDB5. We compared the Hh pathway inhibition and anti-fibrotic effect of MDB5 with GDC-0449 in vitro. Next, we developed MDB5 loaded micelles using our methoxy poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol (PEG-PCC-g-DC) copolymer and characterized for physicochemical properties. We evaluated the therapeutic efficacy of MDB5 loaded micelles in common bile duct ligation (CBDL) induced liver fibrosis, mouse model. We also determined the intrahepatic distribution of fluorescently labeled micelles after MDB5 treatment. Results: Our results show that MDB5 was more potent in inhibiting Hh pathway components and HSC proliferation in vitro. We successfully developed MDB5 loaded micelles with particle size of 40 +/- 10 nm and drug loading up to 10% w/w. MDB5 loaded micelles at the dose of 10 mg/kg were well tolerated by mice, without visible sign of toxicity. The serum enzyme activities elevated by CBDL was significantly decreased by MDB5 loaded micelles compared to GDC-0449 loaded micelles. MDB5 loaded micelles further decreased collagen deposition, HSC activation, and Hh activity and its target genes in the liver. MDB5 loaded micelles also prevented liver sinusoidal endothelial capillarization (LSEC) and therefore restored perfusion between blood and liver cells. Conclusions: Our study provides evidence that MDB5 was more potent in inhibiting Hh pathway in HSC-T6 cells and showed better hepatoprotection in CBDL mice compared to GDC-0449.
引用
收藏
页码:7537 / 7555
页数:19
相关论文
共 50 条
  • [41] Effective treatment of locally advanced periocular basal cell carcinoma with oral hedgehog pathway inhibitor?
    Xiaoyi Hou
    Alexander C. Rokohl
    Monika Ortmann
    Ludwig M. Heindl
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258 : 2335 - 2337
  • [42] Effective treatment of locally advanced periocular basal cell carcinoma with oral hedgehog pathway inhibitor?
    Hou, Xiaoyi
    Rokohl, Alexander C.
    Ortmann, Monika
    Heindl, Ludwig M.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (10) : 2335 - 2337
  • [43] Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
    Jiyu Zhou
    Ningning Huang
    Yitong Guo
    Shuang Cui
    Chaoliang Ge
    Qingxian He
    Xiaojie Pan
    Guangji Wang
    Hong Wang
    Haiping Hao
    ActaPharmaceuticaSinicaB, 2019, 9 (03) : 526 - 536
  • [44] Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
    Zhou, Jiyu
    Huang, Ningning
    Guo, Yitong
    Cui, Shuang
    Ge, Chaoliang
    He, Qingxian
    Pan, Xiaojie
    Wang, Guangji
    Wang, Hong
    Hao, Haiping
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (03) : 526 - 536
  • [45] TREATMENT WITH A NOVEL NOX4 INHIBITOR ATTENUATES LIVER FIBROSIS
    Chen, Xiangling
    Jiang, Xiaosong
    Serizawa, Nobuko
    Szyndralewiez, Cedric
    Page, Patrick
    Torok, Natalie
    HEPATOLOGY, 2011, 54 : 740A - 740A
  • [46] Cthrc1 is a novel inhibitor of TGF-β signaling pathway in liver fibrosis
    Bian, Zhaolian
    Miao, Qi
    Peng, Yanshen
    You, Zhengrui
    Zhang, Haiyan
    Huang, Shanshan
    Ma, Xiong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 396 - 397
  • [47] Hedgehog signaling pathway regulates hexavalent chromium-induced liver fibrosis by activation of hepatic stellate cells
    Yan, Junyan
    Huang, Huarong
    Liu, Zuping
    Shen, Jiayuan
    Ni, Jian
    Han, Jiwei
    Wang, Renjun
    Lin, Derong
    Hu, Baowei
    Jin, Lifang
    TOXICOLOGY LETTERS, 2020, 320 : 1 - 8
  • [48] The Injury-Related Activation of Hedgehog Signaling Pathway Modulates the Repair-Associated Inflammation in Liver Fibrosis
    Shen, Xin
    Peng, Yu
    Li, Hanmin
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [49] The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension
    Duong, Hien T. T.
    Dong, Zhixia
    Su, Lin
    Boyer, Cyrille
    George, Jacob
    Davis, Thomas P.
    Wang, Jianhua
    SMALL, 2015, 11 (19) : 2291 - 2304
  • [50] Polymeric micelles for cutaneous delivery of the hedgehog pathway inhibitor TAK-441: Formulation development and cutaneous biodistribution in porcine and human skin
    Darade, Aditya R.
    Lapteva, Maria
    Ling, Vincent
    Kalia, Yogeshvar N.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 644